Matthew Zirwas, MD

Experts in dermatology share practice pearls and takeaways for treatment of atopic dermatitis.

Expert dermatologists discuss treatment discontinuation as a barrier to achieving desired outcomes in atopic dermatitis.

Aaron S. Farberg, MD, comments on use of different treatments for atopic dermatitis when a patient does not respond to treatment.

Expert dermatologists review the positive impact dupilumab has on quality of life for a patient with atopic dermatitis.

Experts in dermatology discuss efficacy and patient-reported outcomes of topical and systemic JAK inhibitors and dosing guidelines in atopic dermatitis.

Matthew Zirwas, MD, provides insight into the ideal candidates for use of ruxolitinib to treat atopic dermatitis, focusing on patients with sensitive skin.

Expert dermatologists review the safety data of topical ruxolitinib in the treatment of atopic dermatitis.

Alexandra Golant, MD, highlights the positive clinical data of ruxolitinib, a topical JAK inhibitor used for the treatment of atopic dermatitis.

Peter A. Lio, MD, provides an overview of emerging JAK inhibitors in the treatment of atopic dermatitis.

Experts in dermatology consider the use of the Atopic Dermatitis Control Tool and other tools to assess severity of atopic dermatitis.

Aaron S. Farberg, MD, discusses how new therapies have impacted his approach to treatment of atopic dermatitis.

Alexandra Golant, MD, comments on the adverse events of systemic therapies and how emerging nonsteroidal agents have a better safety profile in atopic dermatitis.

Matthew Zirwas, MD, highlights therapies that are available for the treatment of atopic dermatitis, including corticosteroids, calcineurin inhibitors and JAK inhibitors.

Expert dermatologists review the impact of atopic dermatitis on quality of life for both the patient and their families.

Peter A. Lio, MD, provides an overview of the pathophysiology of atopic dermatitis (AD) and the comorbidities often associated with it.

Experts in dermatology share advice on helping fellow physicians stay apprised of the advances in AD and treat their patients more effectively.

Expert dermatologists consider ongoing trials and emerging treatment options for the management of AD.

Experts in dermatology share general guidance for use of topicals, switching from topical to systemic treatment, and when combination therapy is an option for patients with atopic dermatitis.

Omar Noor, MD, and Adelaide A. Hebert, MD, discuss monitoring requirements for various classes of treatments in atopic dermatitis, including topical vs systemic.

Peter A. Lio, MD, reviews treatment options for patients with moderate AD.

Matthew Zirwas, MD, shares goals of therapy for a patient with AD.

Expert dermatologists address the clinical implications of boxed warnings of topical treatments in AD.

Matthew Zirwas, MD, and Omar Noor, MD, comment on their own experience of time to response with topical and systemic treatments of AD.

Peter A. Lio, MD, discusses the durability of topical treatments in AD, including steroids, calcineurin inhibitors, and JAK inhibitors.

Experts discuss long-term efficacy data for topical medications for the treatment of AD.

Matthew Zirwas, MD, and Omar Noor, MD, review a patient scenario where AD disease activity is limited but in difficult to treat locations.

Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.

Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.

Expert dermatologists discuss the durability of long-term use of topical steroids for treatment of atopic dermatitis.

Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.